Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of drug lipidosome/p53 gene complex substance

A p53 gene and liposome technology, applied in the field of tumor treatment, can solve the problems of limited application and easy oxidation and decomposition of resveratrol, and achieve the effects of low cytotoxicity, great clinical application value, and high protein expression.

Inactive Publication Date: 2018-05-15
DALIAN NATIONALITIES UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, resveratrol is easily oxidatively decomposed in the presence of light, heat and oxidants, which limits its application in the food and pharmaceutical industries to a certain extent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of drug lipidosome/p53 gene complex substance
  • Application of drug lipidosome/p53 gene complex substance
  • Application of drug lipidosome/p53 gene complex substance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Dissolve the cationic lipid CDO14 and resveratrol in the organic solvent of methanol and chloroform, add the co-lipid DOPE to fully dissolve, the mass ratio of cationic lipid, resveratrol and co-lipid is 5:1:1, Then vortex and shake for 10 seconds to mix evenly, blow the film with inert gas for 10 minutes, vacuum dry at 25°C for 12 hours, then add water and sonicate at 25°C to prepare an aqueous solution with a concentration of 0.5mg / mL, and separate it by a Sephadex column after centrifugation. Obtain drug liposome, then mix drug liposome and p53 gene, the mass ratio of drug liposome and p53 gene is 1:1, vortex and oscillate for 10 seconds to mix evenly, incubate at 20°C for 10 min, and prepare by electrostatic compounding get.

Embodiment 2

[0033] Dissolve the cationic lipid CDO14 and resveratrol in the organic solvent of methanol, add co-lipid cholesterol to fully dissolve, the mass ratio of cationic lipid, resveratrol and co-lipid is 10:1:1, and then vortex Shake for 15 seconds to mix evenly, blow film with inert gas for 15 minutes, vacuum dry at 30°C for 18 hours, then add water and ultrasonicate at 30°C to prepare an aqueous solution with a concentration of 1.0mg / mL, centrifuge and separate through a Sephadex column to obtain the drug Liposome, and then mix the drug liposome and p53 gene, the mass ratio of drug liposome and p53 gene is 2:1, mix evenly by vortexing for 15 seconds, incubate at 25°C for 15 minutes, and obtain by electrostatic compounding method.

Embodiment 3

[0035]Dissolve cationic lipid CDO12 and resveratrol in the organic solvent of ethyl acetate, add colipid DOPE to fully dissolve, the mass ratio of cationic lipid, resveratrol and colipid is 20:1:1, Then vortex and shake for 20 seconds to mix evenly, blow the film with inert gas for 20 minutes, vacuum dry at 40°C for 24 hours, add water and sonicate at 35°C to prepare an aqueous solution with a concentration of 1.5mg / mL, and separate it by a Sephadex column after centrifugation. Obtain drug liposome, then mix drug liposome and p53 gene, the mass ratio of drug liposome and p53 gene is 3:1, vortex and oscillate for 20 seconds to mix evenly, incubate at 30°C for 20 min, and prepare by electrostatic compounding get.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a drug lipidosome / p53 gene complex substance. The complex substance consists of a drug lipidosome comprising resveratrol and a p53 gene. The application comprises the following steps: taking polypeptide cationic lipids, assistant lipids and resveratrol as raw materials, preparing the drug lipidosome successively by virtue of a film dispersion method, an ultrasonic hydration method and a gel chromatographic column separation method, then mixing the drug lipidosome and the p53 genes, and preparing the drug lipidosome / gene complex substance by virtue of anelectrostatic complexing method. According to the drug lipidosome / p53 gene complex, the activation of the p53 genes is induced by adopting the resveratrol to activate p38MAPK kinase so as to expresswild-type p53 proteins, the death of tumor cells is initiated by synergistically playing the antitumor effect of the lipidosome and p53 genes, and a purpose of treating the tumor can be achieved. Thein-vitro biology research shows that the complex has certain cell proliferation inhibition capacity, the expression of the wild-type p53 protein is high, a novel concept is provided for treating the tumor, and the potential application value is achieved.

Description

[0001] This application is a divisional application with the application number 2017101315500, the application date of March 7, 2017, and the title of the invention "a pharmaceutical liposome / p53 gene complex and its preparation method and application". Technical field: [0002] The present invention relates to a drug liposome / p53 gene complex, more specifically to the preparation of a polypeptide-type cationic drug liposome containing resveratrol and its formation of a novel anti-tumor complex preparation with p53 gene The invention belongs to a novel pharmaceutical preparation in the field of tumor treatment and a preparation method and application thereof. Background technique: [0003] The combined delivery of drugs and genes is a biomedical treatment method that uses carriers to efficiently deliver anticancer drugs and genes into tumor cells, and release drugs and genes in a timely manner to achieve the goal of synergistic treatment. At present, the combined transport t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K9/127A61P35/00A61K31/05
CPCA61K48/0058A61K9/1277A61K31/05A61K2300/00
Inventor 张树彪许晓东李一楠陈会英赵轶男
Owner DALIAN NATIONALITIES UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com